Linde plc (LIN) Market Cap & Valuation Ratios
Linde plc (LIN) has a market cap of $234.6B, a trailing P/E of 32.8 and a price-to-sales ratio of 6.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LINLinde plcFollow LIN — free
—
Price chart with a free account
- Market cap
- 234.6B
- P/E TTM
- 32.8
- Dividend yield
- 1.2%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
specialty chemicals · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| LIN | 235 | 32.8 | 7.3 | 19.5 | 2.1% | +7% | 26% | 12% |
| SHW | 82 | 31.1 | 3.8 | 19.8 | 3.9% | +6% | 16% | 20% |
| ECL | 81 | 38.7 | 5.3 | 22.9 | 2.3% | +7% | 17% | 14% |
| APD | 68 | — | 6.8 | 89.5 | -0.4% | +5% | -5% | -2% |
| PPG | 25 | 15.8 | 1.8 | 10.6 | 5.7% | +5% | 14% | 13% |
| IFF | 24 | 82.6 | 2.9 | 17.1 | 2.2% | -12% | 8% | 3% |
| LYB | 21 | — | 1.0 | 12.7 | 7.4% | -2% | 3% | 4% |
| DD | 18 | — | 2.8 | 17.1 | 3.8% | +3% | 10% | 3% |
| RPM | 13 | 18.3 | 1.8 | 11.9 | 5.6% | +6% | 13% | 14% |
| ALB | 11 | — | 1.9 | 12.6 | 12.1% | +18% | 4% | 2% |
| SOLS | 9.4 | 45.4 | 2.7 | 12.7 | 2.1% | +9% | 16% | 10% |
| Median of these 10 | 34.9 | 2.8 | 14.9 | 3.9% | +5% | 11% | 7% |
P/E 32.8 vs. a peer median of 34.9; EV/Sales 7.3 vs. 2.8. LIN's own P/E sits at the 14th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesAPD and LYB and DD and ALB have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Linde plc — questions
- What is Linde plc's market cap?
- $234.6B.
- What is Linde plc's P/E ratio?
- 32.8 on trailing twelve-month earnings to 2026-06-30.
- What is Linde plc's price-to-sales ratio?
- 6.6.
Every figure on this page comes from Linde plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.